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Even in this highly setumour. However, this is only achievable in about 30% of the patients.
lected group of patients, there is still a high risk of both local and dis-Most long-term survivors of non-small-cell lung cancer (NSCLC) are patients who have had
tant failure. Adjuvant treatments such as chemotherapy (CT) and radiotherapy (RT) have
therefore been evaluated in order to improve their outcome. In patients with stage II and
III, administration of adjuvant platinum-based chemotherapy is now considered the stan-
dard of care, based on level 1 evidence. The role of postoperative radiation therapy (PORT)
remains controversial. In the PORT meta-analysis published in 1998, the conclusions were
that if PORTwas detrimental to patients with stage I and II completely resected NSCLC, the
role of PORT in the treatment of tumours with N2 involvement was unclear and further
research was warranted. Thus at present, after complete resection, adjuvant radiotherapy
should not be administered in patients with early lung cancer. Recent retrospective and
non-randomised studies, as well as subgroup analyses of recent randomised trials evaluat-
ing adjuvant chemotherapy, provide evidence of the possible benefit of PORT in patients
with mediastinal nodal involvement. The role of PORT needs to be evaluated also for
patients with proven N2 disease who undergo neoadjuvant chemotherapy followed by sur-
gery. The risk of local recurrence for N2 patients varies between 20% and 60%. Based on cur-
rently available data, PORT should be discussed for fit patients with completely resected
NSCLC with N2 nodal involvement, preferably after completion of adjuvant chemotherapy
or after surgery if patients have had preoperative chemotherapy. There is a need for new
randomised evidence to reassess PORT using modern three-dimensional conformal radia-
tion technique, with attention to normal organ sparing, particularly lung and heart, to
reduce the possible over-added toxicity. Quality assurance of radiotherapy as well as qual-
ity of surgery – and most particularly nodal exploration modality – should both be moni-
tored. A new large multi-institutional randomised trial Lung ART evaluating PORT in this
patient population is needed and is now under way.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.1. Introduction
Most long-term survivors of non-small-cell lung cancer
(NSCLC) are patients having had a complete surgical resec-tion. However, this is only achievable in about 30% of the
patients. Even in this highly selected group of patients,
there is still a high risk of both local and distant failure.
Adjuvant treatments such as chemotherapy (CT) and
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improve their outcome. For years, the use of adjuvant CT
and/or RT was a controversial issue, as neither seemed to
have any impact on survival in individual trials that were of-
ten under-powered. However, the meta-analysis including tri-
als comparing surgery alone to surgery + adjuvant CT
published in 1995 showed a modest survival benefit of 5%
in completely resected patients having received postopera-
tive cisplatin-based adjuvant CT compared with patients
without CT [1]. The beneficial effect of adjuvant CTwas con-
firmed in large trials initiated after the meta-analysis. It var-
ies between 4% and 15% at 5 years in favour of surgery plus
adjuvant chemotherapy [2–8]. Furthermore, the meta-analy-
sis published in 2010 including 8447 patients with updated
data from the old trials, and data from all recent trials show
an absolute increase in survival of 4% at 5 years (from 60%
to 64%, P < 0.0001) [9]. Thus, most clinicians now consider
adjuvant CT as standard treatment in patients with stages
II and III completely resected lung cancer. Updated survival
analysis of two individual trials has also been published
with contrasting results as to the persistent long-term ben-
eficial effect of adjuvant chemotherapy [10,11]. On the other
hand, concerning adjuvant RT, an individual data-based
meta-analysis evaluating the role of postoperative radiother-
apy (PORT) after surgery for NSCLC was also undertaken in
the 1990s: it showed that adjuvant RT could be deleterious
in patients with early lung cancer (i.e. stages I and II) but
that in more advanced lung cancer (i.e. stage IIIA) it should
be better explored in new studies, especially in patients with
mediastinal involvement [12]. At the current time, adjuvant
treatment is focused on chemotherapy and the risk of dis-
tant metastases rather than on postoperative radiotherapy
which may also have an impact on disease control. It seems,
however, that 20–60% of patients may be at risk for loco-re-
gional recurrence. In view of the high proportion of patients
still suffering from local failure after a complete resection
and adjuvant chemotherapy, a new interest in PORT has
been generated, even though PORT remains a controversial
issue. We have therefore reviewed the evidence regarding
adjuvant radiotherapy in completely resected NSCLC in
2013. Assessing the patterns of failure after surgery and
the possible PORT-related toxicity is helpful in evaluating
the benefit/risk ratio of postoperative therapy. Even if the
risk of local recurrence in early lung cancer is generally con-
sidered to be small in comparison with the risk of distant
recurrence, the rates of local failure are highly variable in
the literature, ranging from 6% to 45% in stage I and from
7% to 55% for stage II disease. There are various reasons
for this: problem of definition, and local failures often not
reported when they occur at the same time as distant
metastases or after distant failure.
An additional difficulty in the decision to administer adju-
vant treatment may be the new tumour-node-metastasis
(TNM) classification [13,14]. Five-year rates of locoregional
recurrence (LRR) for stages IA, IB, IIA, IIB and IIIA disease
using TNM-6 were 16%, 26%, 43%, 35% and 40%, respectively.
Using TNM-7, corresponding rates were 16%, 23%, 37%, 39%
and 30%, respectively, and there about 10–15% ‘stage shifters’
[14,15].2. Studiesevaluatingmediastinalpostoperative
radiotherapy
Several retrospective studies, contemporaneous to the studies
included in the meta-analysis, have shown that the risk of lo-
cal recurrence could be reduced by PORT (25–35%) in historical
comparisons [16–22]. However, this finding was not corrobo-
rated by most randomised trials.
In this review article, we will focus on randomised trials
and on the meta-analyses on PORT [12,23–29]. Several of the
trials are old, conducted in the era before computed tomogra-
phy (CT) scan and positron emission tomography (PET), with
patients treated with cobalt 60 (Co60) or even orthovoltage
therapy; this resulted in a higher risk of both morbidity and
mortality [30,31]. Furthermore, irradiated volumes were often
large, fractionations often superior to 2 Gy daily, all these fac-
tors contributing to a higher morbidity; other technical fac-
tors such as the absence of CT-based planning in most trials
or the use of spinal cord blocks which potentially block medi-
astinal disease may explain several LRRs. As previously sta-
ted, the rates of local failures at 5 years vary according to
stage, and in several studies patients at low risk for LRR were
included, possibly obscuring a radiation-induced benefit in
higher-risk patients.3. Randomised trials of adjuvant radiotherapy
in stage I resected NSCLC
Van Houtte et al. [23] conducted a randomised trial in 175 pa-
tients who had a complete resection and had no lymph-node
involvement. The 5-year survival rate was 24% in the RT arm
versus 43% in the control arm. PORTwas significantly delete-
rious, especially after pneumonectomy (16% in the PORT arm
versus 43% in the control arm). They concluded that TRT
should not be recommended in N0 patients. A more recent
Italian randomised trial compared PORT at the dose of 50.4
Gy to no PORT in 104 patients with pathological stage I disease
[24]. The patients included in this study benefited from more
modern radiotherapy: all patients had a CT-planned treat-
ment, linear accelerators were used and treatment volumes
– including the bronchial stump and ipsilateral hilum – were
small. Radiotherapy significantly decreased the risk of local
recurrence from 23% in the control group to 2.2% in the PORT
group (P = 0,002) but there was no significant difference in
terms of 5-year overall survival (67% in the PORT group and
58% in the control group). There was no over-added toxicity
in the PORT group. However, it may be argued that patients
with pathological stage I NSCLC have such a low risk of local
recurrence, that routine PORT is generally not recommended
except for patients with R1 or R2 resections.4. Randomised trials of adjuvant radiotherapy
in stages II and III resected NSCLC
The Lung Cancer Study Group conducted a randomised study
including 230 patients with stage II and III squamous-cell car-
cinoma to evaluate postoperative PORT at the dose of 50 Gy
[25]. PORT significantly decreased the risk of local recurrence:
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not translate into a demonstrable overall survival benefit (5-
year survival rate around 40% in both arms), since most recur-
renceswere outside the radiation field orwere distant failures.
However a subgroup analysis suggested that PORT could pro-
long disease-free interval in patients with N2 disease. The de-
sign of the Medical Research Council study was quite similar
but also included patients with adenocarcinoma [26]. Patients
with pathologically staged T1–2, N1–2 NSCLC were randomly
assigned to receive either surgery alone or surgery and PORT
at the dose of 40 Gy in 15 fractions. The results confirmed pre-
vious studies: therewas no advantage for survival in the PORT
group over the control arm, but in the N2 subgroup analysis
there was a non-significant trend towards improved survival
and local control. Thus, the authors concluded that there
was no indication for PORT in N1 disease, but the question re-
mained open for N2 patients. The largest trial evaluating PORT
included 728 patients (221 with stage I, 180 with stage II and
327 with stage III disease) [27]. It demonstrated that PORT
had a detrimental effect on survival: the 5-year survival rate
was 43% for the control group and 30% for the RT group
(P = 0.002). In terms of 5-year rate without local recurrence,
there was a trend in favour of PORT among N2 patients. The
excess mortality rate in the radiotherapy group was due to
an increase in intercurrent deaths. In a Chinese randomised
study of 366 completely resected patients with N1 or N2 nodal
disease, PORT significantly reduced the rate of local relapses:
the local failure rate was 12.7% versus 33.2% in the control
group (P = 0.01), but this had no impact on survival [28].
In conclusion, before the meta-analysis was published, the
role of PORTwas unclear as the individual trials showed con-
flicting and inconclusive results. They did not have the statis-
tical power to detect moderate survival differences. Thus the
PORT meta-analysis group gathered individual data on 2128
patients from nine randomised trials [12]. Its results indicated
that PORT had a significant detrimental effect on survival,
with an absolute decrease of 7% at 2 years, reducing the over-
all survival from 55 to 48% (P = 0.001). Subset analyses sug-
gested that PORT could be deleterious in terms of overall
survival, predominantly among patients who had a complete
resection and no mediastinal involvement (either pN0 or
pN1). However, than authors could observe a 24% relative
reduction in local recurrence rate (all stages together), so that
the question of PORT in pN2 patients who have a high local
recurrence rate remained valid and could warrant further re-
search. This overview was updated in 2005 and included an
additional trial by Trodella et al. in the analysis; it still showed
PORT to be detrimental, with an 18% relative increase in the
risk of death [32]. A very recent letter updating the results of
the meta-analysis was published using different statistical
methods, confirming that PORT should not be routinely used
unless there is supporting evidence from new trials of mod-
ern PORT [33]. Unfortunately no phase III trial evaluating
more modern PORT versus no PORT has been published since
1998. However, there have been studies on adjuvant chemo-
therapy as well as chemoradiotherapy. The already men-
tioned meta-analysis on the role of adjuvant chemotherapy
in completely resected patients also comprised a second anal-
ysis based on 13 trials and 2660 patients, mostly stage III pa-
tients, and compared surgery plus radiotherapy versussurgery plus radiotherapy and chemotherapy [9]. It showed
a significant improvement in survival of 4% at 5 years (from
29% to 33%). It should be outlined that a similar 4% absolute
benefit was observed in the analysis of trials comparing sur-
gery with surgery and chemotherapy that included mainly
patients with stages I and II NSCLC. Thus the effect of chemo-
therapy was similar irrespective of which loco-regional treat-
ment was used: surgery alone or surgery plus PORT. The
authors concluded that, as this meta-analysis was not de-
signed to study the effect of PORT, randomised trials were
needed to assessmodern radiotherapy as adjuvant treatment.
5. Studies on adjuvant chemoradiotherapy in
stage II and III patients
Until 1998, PORT was considered the standard treatment by
many clinicians in stage II and stage III patients; thus the East-
ern Cooperative Group (ECOG) completed a prospective trial
comparing PORTat the dose of 50.4 Gy in 1.80 Gy fractionswith
PORT and concomitant chemotherapy combining etoposide
and cisplatin [34]. The 3-year survival rate was, respectively,
52% in the PORT arm and 50% in the combined treatment
arm (P = 0.56). The loco-regional recurrence rate within the
radiotherapy field was about 13% in both arms and was there-
fore smaller than the rates reported in the literature. A better
standardised surgical treatment may explain these results in
terms of local control, as well as the use of more modern
radiotherapy using CT-scan-based planning. The protocol re-
quired a thoroughmediastinal lymph-node dissection or sam-
pling according to the American Thoracic Society lymph node
definitions [35,36]. There was a significant difference (P < 0.05)
between the recurrence rate of patients with mediastinal dis-
section (50%) and those with mediastinal sampling (60%) [37].
Thus the authors concluded that cisplatin and VP-16 adminis-
tered concomitantly with PORT did not prolong survival or
modify local failures compared to PORT alone. Other phase II
trials have evaluated adjuvant concomitant chemoradiation
in stage II and IIIA patients [38,39]. In the RTOG 9705 phase II
trial, where 86 patients had concurrent paclitaxel/carboplatin
and PORT at the dose of 50.4 Gy, the 3-year progression-free
and overall survival ratewas respectively 50% and 61%, and lo-
cal failure was a component of first failure in 15% of patients
[38]. In another phase II study that included 42 patients (40%
of pN1 and 60% of pN2 patients) treated with a similar regi-
men, the 2- and 5-year Kaplan–Meier estimates of local regio-
nal control were 92% and 88%, whereas the 2- and 5-year
overall survival rate was 72% and 44%, respectively [39]. Even
if these results seemed better that those reported in the Inter-
group trial, no randomised trial was undertaken, so that adju-
vant concomitant chemoradiation after complete surgery
cannot be considered as a standard treatment.6. Postoperative radiotherapy (PORT): toxicity
issues
The excess of toxicity (mostly cardiac and pulmonary) and
non-cancer-related deaths observed after PORT in the meta-
analysis trials can probably be explained by old radiation 2D
techniques, excessive volumes of radiation, too large doses
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nately, the authors could not collect data on toxicity or causes
of intercurrent deaths in the different studies. Late cardiac
complications that are described after mediastinal radiother-
apy are linked to the total dose, the fraction size, the irradi-
ated volume, the technique of irradiation, as well as
comorbidities (tobacco use, overweight) [40,41]. Pulmonary
complications such as pneumonitis and lung fibrosis can also
be observed, but they occur earlier; there are strong volume
and fractionation effects [42]. In a recent prospective study
of 291 patients, cardiopulmonary functions as well as quality
of life were evaluated prospectively at baseline and at 2 years
among 171 pN2 patients who had PORT and 120 pN1 patients
who did not have PORT. The authors found no significant dif-
ference in terms of cardiopulmonary morbidity among pa-
tients alive at 2 years [43]. The administration of certain
radiosensitising drugs such as gemcitabine may increase this
risk. In the phase II trial RTOG 9705 evaluating adjuvant con-
comitant chemo-radiotherapy, a 6% crude incidence of late
pulmonary toxicity and similarly a 5% rate of late cardiac tox-
icity of grade 3 or over were observed [38]. Miles et al. elabo-
rated a mathematical model to describe the tumour stage-
and field-size-dependent risks/benefits of postoperative
radiotherapy and showed that RT-induced mortality was
strongly dependent on field size [44]. In the largest published
randomised trial, Dautzenberg could determine that the use
of fraction sizes >2 Gy resulted in a high risk of late toxicity
[27]. The risk of non-cancer-related death was, respectively,
7% in the control group, 16–18% among patients who had dai-
ly RT fractions 62 Gy and 26% among those who had higher
doses per fraction. Several studies reported reduced toxicity
and mortality with more modern PORT. A retrospective study
focusing on toxicity issues showed that PORT could be admin-
istered safely if patients were treated with more modern
treatment techniques, more limited volumes of irradiation,
daily fraction sizes 62 Gy and total doses 654 Gy [45]. The
4-year actuarial rate of death from intercurrent disease
(DID) for patients treated with PORT within the E3590 trial
was 12.9%: not significantly different from the 10.1% expected
rate of DID observed in a control population matched for age
and gender and corrected for smoking status [46]. A Surveil-
lance, Epidemiology and End Results (SEER) data-based study
analysed deaths from heart disease in a group of 6148 pN1 or
pN2 patients operated between 1983 and 1993 who were fol-
lowed up until 2005 [47]. Amongst them, 58% had PORT. PORT
delivery was associated with an increase in the hazard for
heart disease. However, this increase was only significant in
patients treated between 1988 and 1993. For the authors, this
could reflect the impact of more modern radiotherapy tech-
niques utilised in the second half of the 1990s on morbidity.7. Should PORT be considered for patients
with mediastinal involvement?
Lally et al. have reported on PORT in a population-based co-
hort of 7465 patients with stage II and III non-small-cell lung
cancer who had surgery [48]. They selected from the SEER
database patients treated between 1988 and 2002, out of
which 47% received PORT. Patients who had PORT were pre-sumably treated with more modern radiotherapy techniques
than patients included in the meta-analysis. The 5-year sur-
vival rate was 20% in the no-PORT versus 27% in the PORT
group (P = 0.0036). The authors concluded that PORT offered
a significant survival benefit for patients with N2 nodal dis-
ease, but that there was a detrimental effect for patients with
N0 or N1 nodal disease. However, as with any retrospective
study using a large database, one should be cautious with
the results. Another recently published trial by Douillard
et al. also suggested the possible impact of PORT on survival
in patients included in the adjuvant Navelbine International
Trialist Association (ANITA) randomised trial [5,49]. In a sub-
group analysis according to nodal status, survival was im-
proved in patients with pN2 disease who received PORT,
both in the chemotherapy (MS 23.8 versus 47.4 months) and
observation arms (median 12.7 versus 22.7 months). The
authors concluded that their retrospective evaluation sug-
gested a positive effect of PORT administered after CT in
pN2 disease, and that these results supported further evalua-
tion of PORT in prospectively randomised studies. They also
could show as in the meta-analysis that PORT seemed to be
deleterious in pN1 patients. However, most studies do not
specify the exact location of locoregional recurrence. In a
large retrospective study of 406 patients with pN2 nodal
involvement, the local recurrence rate among the 332 evalu-
ated patients was 39.2% and most of these recurrences oc-
curred in the mediastinum [50]. Some additional interesting
issues concerning local control have been outlined by retro-
spective studies. Kelsey observed that left-sided tumours
tended to recur in the contralateral mediastinum more fre-
quently than right-sided tumours, and this could be ex-
plained by lymph node exploration techniques as left
lymph-node exploration is considered more difficult than
right-sided lymph-node exploration [37,51]. Sawyer et al. have
tried to divide pN2 patients into three different subgroups
according to their respective risk of failure: high-risk (in cases
of multiple distant mediastinal nodes involved), intermedi-
ate-risk (in cases of involvement of inferior nodes or superior
nodes with eventual invasion of hilar nodes). and low-risk (if
there is no hilar node involvement) [22]. Several recent mono-
institutional studies have evaluated PORT retrospectively in
patients with pN2 involvement and they show positive results
not only in terms of local recurrence but also in terms of sur-
vival [52–55]. Furthermore, most patients had no adjuvant
chemotherapy, no staging according to today’s standards
and this delineates the importance of a new randomised
study comparing PORT to no PORT in such a frequent cancer
as NSCLC.
Another issue is whether patients with provenmediastinal
involvement and who have neoadjuvant chemotherapy
should have PORT after a complete resection. Many clinicians
treat patients with clinical N2 involvement with preoperative
chemotherapy. Several studies, as well as a meta-analysis
based on literature, have indeed suggested a benefit in terms
of survival in favour of preoperative chemotherapy [56–60].
Mediastinal down-staging has been shown to be an important
prognostic factor [57,59]. However, the recurrence rate can be
quite high as seen in the updated results of a phase II trial of
neoadjuvant chemotherapy where at 5-year follow-up, 60% of
patients had local relapse [61]. Another recently published
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N2 patients down-staged after neoadjuvant chemotherapy.
The 5-year local-regional failure (LRF) rate was 31%, and most
locoregional recurrences appeared in the mediastinal (92%)
and hilar lymph nodes (23.7%), the risk being particularly high
in case of N1 disease [62]. In another retrospective study, the
5-year actuarial local control rate was 82% among patients gi-
ven PORT versus 35% who had no PORT. Thus even if PORT
after neoadjuvant chemotherapy followed by surgery may re-
duce local recurrence as reported in small retrospective stud-
ies, this remains to be proven [63,64] Thereby the question of
PORT is also valid among patients who have histologically
proven N2 disease before preoperative chemotherapy, what-
ever their response is: persistent mediastinal involvement
or mediastinal down-staging (from N2 histologically proven
to pN0 or pN1). No randomised study has been published on
this issue.
8. Importance of surgery and preoperative
staging in the perspective of modern adjuvant
radiotherapy
New data concerning PORT should take into consideration the
quality of surgery and the progress made in terms of preoper-
ative staging or re-staging after neoadjuvant chemotherapy.
At present most patients considered for surgery are much
better selected on the basis of a PET scan and brain imaging.
PET–CT is highly sensitive and specific in detecting mediasti-
nal nodal spread and extracranial metastases [65,66]. After
induction chemotherapy for patients with N2 involvement,
repeated FDG-PET may select surgical candidates among pa-
tients with mediastinal down-staging or persistent minor dis-
ease [67].
In the past years there has been an important collaborative
effort of thoracic surgeons to define lymph-node exploration
and complete resection. The European Society of Thoracic
Surgeons (ESTS) has proposed guidelines for appropriate
intraoperative and preoperative lymph-node staging [68,69].
The International Association for the Study of Lung Cancer
(IASLC) staging committee has proposed a definition of com-
plete resection [70]. All resection margins – including bron-
chial, venous and arterial stumps and peribronchial soft
tissue – should be microscopically free of disease. Systematic
nodal examination should comprise at least three intrapul-
monary and hilar nodes and at least three nodes from the fol-
lowing mediastinal nodal stations according to the location of
the primary tumour. There is no consensus about whether
the highest mediastinal node that has been explored and re-
moved should be negative. It is also unclear whether the ex-
tent of mediastinal exploration can affect long-term
survival. Even if randomised trials have been performed com-
paring these two mediastinal approaches, there still is a de-
bate between advocates of radical mediastinal node
dissection who claim not only a potential prognostic benefit
but a better tumour staging and treatment, and opponents
of the radical approach because of higher morbidity and mor-
tality and possibly a negative effect on survival because of im-
paired local immunity [71–73].
Considering resected patients, an exploratory analysis of
the IASLC database studied survival after complete resectionin relation to the extent of node involvement using the zonal
concept [74,14]. Three groups were identified, with significant
differences in terms of survival. Group 1 with single-zone N1
disease had a 5-year survival rate of 48%. Group 2 consisting
of patients with multizone N1 and single-zone N2 disease
had 5-year survival rates around 35%. Group 3 comprised pa-
tients with multizone N2 disease, and the 5-year survival rate
did not exceed 20%. More recently, two large retrospective
studies have tried to question whether the number of lymph
nodes involved were of added prognostic significance com-
pared with the pathological nodal stage (pN category)
[75,76]. However, among the 2538 pathologically staged N1
and N2 cases in the IASLC database, such results were not ob-
served [77]. The importance of mediastinal node involvement
seems therefore the best and most consensual prognostic
factor.9. Implications for a new trial evaluating PORT
At present, based on level 1 evidence, patients who have had a
complete resection of the primary tumour with mediastinal
lymph-node dissection showing no mediastinal involvement
(pN0 and pN1) should not have PORT. The issue of PORT is
not as clear among patients with N2 mediastinal involve-
ment. Indication of PORT is currently debated for each indi-
vidual patient with mediastinal involvement. A new trial is
needed addressing PORT in stage IIIA patients. Conforma-
tional radiotherapy should be mandatory so as to reduce tox-
icity and improve outcome [78–80]. The irradiation volume
should take into account the data of thoracic CT scan and
the eventual PET scan data before surgery, as well as the
description of mediastinal exploration and histopathological
results. A recent study has shown there are wide variations
in target volume definition for PORT [81]. Based on previous
studies, it seems reasonable to treat only involved lymph-
node stations and uninvolved stations at high risk to better
protect surrounding normal structures and consequently
minimise treatment-related mortality [82–85]. An atlas of
CT-based definition of thoracic lymph-node stations may be
helpful [86].
In the ongoing study LungART, the irradiation volume in-
cludes the lymph-node stations involved according to the
pathological report as well as lymph-node stations consid-
ered at high risk of involvement according to tumour location
[87].
Among pN2 patients included in the PORT overview, the
high rate of distant metastases diluted any real effect of local
control on overall outcome. As the standard treatment for pa-
tients with mediastinal involvement has changed in the last
10 years from surgery plus adjuvant radiotherapy to surgery
plus chemotherapy, and selection of surgical candidates has
evolved with PET–CT as well as minimally invasive staging
procedures, it is of utmost importance to evaluate whether
modern adjuvant radiotherapy can improve survival in pa-
tients after complete resection and adjuvant chemotherapy.
Lung ART is a randomised trial evaluating modern PORT in
patients with mediastinal involvement. Patients may have
chemotherapy in the neoadjuvant setting or adjuvant setting.
It is an inter-group study involving the Intergroupe Franco-
128 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 2 3 –1 3 0phone de Cancerologie Thoracique (IFCT 0503), a United King-
dom group (UK 11/NW/0075) and the EORTC (EORTC 22055-
08053) (NCT00410683). Another trial is ongoing in China com-
paring adjuvant chemotherapy followed by PORT to adjuvant
chemotherapy alone (NCT00880971). Such studies could re-
sult into an optimisation of standard care in operable stage
III patients.Conflict of interest statement
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